Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index; none of the 272 sources its claims cite is checked for support yet.

Islet cell failure in type 2 diabetes

Open access
Prentki, M. · 2006 · Journal of Clinical Investigation

Abstract

The major focus of this Review is on the mechanisms of islet beta cell failure in the pathogenesis of obesity-associated type 2 diabetes (T2D). As this demise occurs within the context of beta cell compensation for insulin resistance, consideration is also given to the mechanisms involved in the compensation process, including mechanisms for expansion of beta cell mass and for enhanced beta cell performance. The importance of genetic, intrauterine, and environmental factors in the determination of "susceptible" islets and overall risk for T2D is reviewed. The likely mechanisms of beta cell failure are discussed within the two broad categories: those with initiation and those with progression roles.

Overview

CoChat Summary

## TL;DR

This is a 2006 review arguing that type 2 diabetes develops when insulin-resistant islets can no longer sustain compensatory b cell function, leading first to dysfunction and then progressive loss of b cell mass. It emphasizes that “susceptible” islets are shaped by genetic, intrauterine, and environmental factors, and that hyperglycemia accelerates damage through glucotoxic and glucolipotoxic mechanisms.

## Key findings

  • In longitudinal studies, insulin levels rise during the normoglycemic and prediabetes phases and then decline when fasting glycemia exceeds the upper normal limit of 5.5 mM, marking b cell failure.
  • A longitudinal study in Pima Indians found that b cell dysfunction was the major determinant of progression from normoglycemia to diabetes.
  • In autopsy pancreata from 124 subjects, the paper reports a 40% and 63% loss of islet b cell volume in obese subjects with impaired fasting glucose and T2D, respectively, compared with weight-matched controls; lean T2D subjects had a 41% loss versus lean controls.
  • The paper reports that the STOP-NIDDM trial showed acarbose treatment of IGT subjects reduced the risk of progression to diabetes by 36%.

## Methods

  • Narrative review of mechanistic, animal, human postmortem, genetic, and epidemiologic studies on islet b cell compensation and failure in obesity-associated T2D.
  • Synthesizes findings from rodent models (including ZF, ZDF, DBA2, GK, and IUGR models) and human islet/pancreas studies, including a transcript profiling study of 7 normal and 5 T2D human islet samples.
  • Main analysis is integrative and conceptual: it organizes evidence into mechanisms that promote compensation and mechanisms with initiation versus progression roles in b cell failure.

## Limitations

  • The paper states that the mechanisms of b cell compensation are “not fully understood,” and that the role of several proposed factors remains to be established or warrants further investigation.
  • It explicitly notes uncertainty about several mechanisms, including whether nonimmune islet inflammation contributes in vivo, whether IAPP is causal in b cell dysfunction and demise, and whether reduced ARNT expression is an early defect or a consequence.
  • Evident from the text: this is a review, not a new experimental study, so its conclusions depend on the quality and consistency of the cited animal and human studies rather than on a single primary dataset.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci29103

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 1 Not valid · 164 Not checked · 38 Own results and interpretations

116 more claims

Create a free account to see all 203 claims and to verify the 272 references still open.

See all claims — free account
  • It may state two separate claims as one. 71
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 132 references

Cited by

See all 1,690

Metadata

Authors
Prentki, M.
Affiliations
Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author
Prentki, M.
Venue
Journal of Clinical Investigation
Published
2006-07-03
Volume
116
Issue
7
Pages
1802-1812
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1598254642
Cited by
1,690
References
132
Citations by year
2026: 52 · 2025: 52 · 2024: 46 · 2023: 54 · 2022: 68 · 2021: 95 · 2020: 95 · 2019: 111 · 2018: 90 · 2017: 109 · 2016: 112 · 2015: 107 · 2014: 131 · 2013: 97 · 2012: 98
FWCI
13.11
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • ANU Open Research (Australian National University) (submittedVersion)
Funders
  • ACT Government
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK063356, DK63356)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
beta-cell failure, type 2 diabetes, obesity, beta-cell compensation, beta-cell mass expansion, insulin resistance, genetic susceptibility, intrauterine factors, environmental risk factors, beta-cell dysfunction
MeSH terms
Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Disease Progression, Genetic Predisposition to Disease, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Islet cell failure in type 2 diabetes. https://app.cochat.ai/papers/10.1172/jci29103
The paper
Prentki, M. (2006). Islet cell failure in type 2 diabetes. Journal of Clinical Investigation. https://doi.org/10.1172/jci29103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.